- Home
- KRNY vs ZNTL Comparison
KRNY vs ZNTL Comparison
Compare KRNY & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRNY | ZNTL |
|---|---|---|
| Founded | 1884 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.9M | 468.9M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KRNY | ZNTL |
|---|---|---|
| Price | $8.13 | $4.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $8.50 | $6.60 |
| AVG Volume (30 Days) | 256.1K | ★ 4.5M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.65% | N/A |
| EPS Growth | ★ 130.22 | 18.03 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,580,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | N/A |
| P/E Ratio | $25.95 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $5.76 | $1.13 |
| 52 Week High | $8.50 | $6.95 |
Technical Indicators
Market Signals| Indicator | KRNY | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 55.00 |
| Support Level | $7.77 | $1.53 |
| Resistance Level | $8.33 | $6.95 |
| Average True Range (ATR) | 0.22 | 0.79 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 83.64 | 34.32 |
Price Performance
Historical ComparisonAbout KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.